GLP-1 Genetics: Why Some People Lose Cravings and Others Don't

The Variation Problem

One of the most consistent findings across GLP-1 addiction research is that the effects are not universal. Not everyone taking semaglutide for weight loss reports losing interest in alcohol. Not every smoker on a GLP-1 medication finds cigarettes unappealing. The WashU BMJ study found a 14% average reduction in new substance use disorders — meaningful at population scale, but clearly not affecting every individual equally.

This variability raises a fundamental question: what determines who responds and who doesn't? The answer likely involves genetics, and emerging research is beginning to identify specific variants that may predict anti-craving effects.

The rs6923761 Variant

A human genetic association study identified a variant of the GLP-1 receptor gene — rs6923761 — that is associated with increased alcohol self-administration and altered brain responses in reward-related areas as revealed by functional MRI imaging. People carrying this variant showed different activation patterns in regions like the VTA and nucleus accumbens when exposed to alcohol-related cues.

This finding is significant because it suggests that genetic variation in GLP-1 receptor structure or expression can directly influence how the reward system responds to addictive stimuli. By extension, it implies that the same genetic variation might predict how strongly GLP-1 agonist medications affect craving in a given individual.

Pharmacogenomics and Addiction

The concept of using genetic information to predict medication response — pharmacogenomics — is already established in other areas of medicine. In psychiatry, genetic testing can help predict which antidepressants are most likely to work for a given patient. In oncology, tumor genotyping guides targeted therapy selection.

For addiction medicine, pharmacogenomics has been slower to develop, partly because the genetics of addiction are polygenic (many genes contribute) and partly because environmental factors play an enormous role. But the identification of GLP-1 receptor variants associated with reward processing opens a potential pathway toward personalized addiction treatment.

If clinicians could test for GLP-1R variants before prescribing semaglutide for craving reduction, they could identify patients most likely to benefit — and avoid the cost, side effects, and therapeutic delay of prescribing a medication that might not work for a given individual's neurobiology.

Beyond Single Genes

The rs6923761 variant is unlikely to be the full story. Response to GLP-1 medications probably involves variations across multiple genes affecting dopamine receptor density, GABA neurotransmission, gut hormone sensitivity, and blood-brain barrier permeability (which affects how much of the drug reaches brain reward centers).

Additionally, metabolic factors may play a role. Several studies have noted that GLP-1's anti-addiction effects may be stronger in people with obesity or insulin resistance — populations where GLP-1 signaling is already disrupted. People with normal metabolic function may have less room for GLP-1 agonists to modulate their reward circuitry.

What We're Waiting For

The current state of GLP-1 pharmacogenomics in addiction is early-stage. Large-scale studies correlating genetic profiles with clinical outcomes (craving reduction, relapse rates, substance use changes) have not yet been conducted. The ongoing clinical trials — particularly the larger Phase 3 AUD trials and the NIDA STAR trial — could potentially include genetic sub-analyses that advance this field.

Until then, predicting who will and won't respond to GLP-1 medications for craving reduction remains impossible. But the genetic evidence that exists points clearly in one direction: individual variation in GLP-1 receptor biology matters for addiction, and personalized treatment is eventually coming.